drugset
drugset / Trial / NCT05086107

Pharmacokinetics and Safety of BV100 Administered as Single Intravenous Infusion to Subjects With Renal Impairment

NCT05086107 ↗

Phase 1 Completed 48 enrolled BioVersys AG Clinical Research Units Hungary · collab
NaSequentialOpen-labelBasic science

Summary

To investigate the pharmacokinetics (PK) of rifabutin in subjects with renal impairment after single intravenous (IV) infusion of BV100

Timeline

Start
2021-10-08
Primary completion
2022-05-30
Completion
2023-01-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Rifabutin Small molecule — Intravenous

Indications

impaired renal function disease